Volume 10,Issue 1
Fall 2025
Fecal Microbiota Transplantation against Gut Colonization Using a Multidrug-Resistant Organism
Background: Fecal microbiota transplantation against gut colonization using a multidrug-resistant organism is a technique used to treat infections through normalizing the gut microbiota via fecal microbiota transplantation in patients with confirmed colonization by carbapenem-resistant Enterobacteriaceae (CRE) or vancomycin-resistant enterococci (VRE) based on a fecal culture test within the past one week. In this study, we aimed to determine the safety and effectiveness of this technique. Methods: The safety and effectiveness were assessed via a systematic review. A literature search was conducted using five Korean databases, such as KoreaMed, and international databases, including Ovid-MEDLINE, Ovid-EMBASE, and Cochrane Library. Results: Main results are described here. From the studies retrieved using the aforementioned search strategy, the remaining 581 studies were screened using the inclusion and exclusion criteria, resulting in the selection of nine studies for further consideration. In terms of safety, many studies reported deaths and adverse reactions associated with different causes. Fewer studies reported the rate of colonization; however, the effect of colony rate was inconsistent when compared to no treatment group. Additionally, none of the studies assessed the recurrence rate, a decrease in the prevalence of diseases related to infection by multidrug-resistant bacteria, and the quality of life. Conclusion: Fecal bacterial colonization for the decolonization of intestinal multidrug-resistant bacteria was evaluated using a technique that requires further research as there is insufficient literature evidence to validate its safety and efficacy in treating infections through normalizing the intestinal flora of patients with confirmed colonization by CRE or VRE.
1. Crouzet L, Rigottier-Gois L, Serror P. (2015). Potential Use of Probiotic and Commensal Bacteria as Non-Antibiotic Strategies against Vancomycin-Resistant Enterococci. FEMS Microbiol Lett, 362: fnv012.
2. Ghani R, Mullish BH, McDonald JAK, et al. (2021). Disease Prevention not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized with Multidrug-Resistant Organisms. Clin Infect Dis, 72: 1444–1447.
3. Moher D, Liberati A, Tetzlaff J, et al. (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med, 6: e1000097.
4. Huttner BD, de Lastours V, Wassenberg M, et al. (2019). A 5-Day Course of Oral Antibiotics Followed by Faecal Transplantation to Eradicate Carriage of Multidrug-Resistant Enterobacteriaceae: A Randomized Clinical Trial. Clin Microbiol Infect, 25: 830–838.
5. Saïdani N, Lagier JC, Cassir N, et al. (2019). Faecal Microbiota Transplantation Shortens the Colonisation Period and Allows Re-Entry of Patients Carrying Carbapenamase-Producing Bacteria into Medical Care Facilities. Int J Antimicrob Agents, 53: 355–361.
6. Battipaglia G, Malard F, Rubio MT, et al. (2019). Fecal Microbiota Transplantation Before or After Allogeneic Hematopoietic Transplantation in Patients with Hematologic Malignancies Carrying Multidrug-Resistance Bacteria. Haematologica, 104: 1682–1688.
7. Davido B, Batista R, Fessi H, et al. (2019). Fecal Microbiota Transplantation to Eradicate Vancomycin-Resistant Enterococci Colonization in Case of an Outbreak. Med Mal Infect, 49: 214–218.
8. Dinh A, Fessi H, Duran C, et al. (2018). Clearance of Carbapenem-Resistant Enterobacteriaceae vs Vancomycin-Resistant Enterococci Carriage After Faecal Microbiota Transplant: A Prospective Comparative Study. J Hosp Infect, 99: 481–486.
9. Bilinski J, Grzesiowski P, Sorensen N, et al. (2017). Fecal Microbiota Transplantation in Patients with Blood Disorders Inhibits Gut Colonization with Antibiotic-Resistant Bacteria: Results of a Prospective, Single-Center Study. Clin Infect Dis, 65: 364–370.
10. Davido B, Batista R, Michelon H, et al. (2017). Is Faecal Microbiota Transplantation an Option to Eradicate Highly Drug-Resistant Enteric Bacteria Carriage? J Hosp Infect, 95: 433–437.
11. Jang MO, An JH, Jung SI, et al. (2015). Refractory Clostridium difficile Infection Cured with Fecal Microbiota Transplantation in Vancomycin-Resistant Enterococcus Colonized Patient. Intest Res, 13: 80–84.
12. Stripling J, Kumar R, Baddley JW, et al. (2015). Loss of Vancomycin-Resistant Enterococcus Fecal Dominance in an Organ Transplant Patient with Clostridium difficile Colitis After Fecal Microbiota Transplant. Open Forum Infect Dis, 2: ofv078.
13. Russell DL, Flood A, Zaroda TE, et al. (2008). Outcomes of Colonization with MRSA and VRE among Liver Transplant Candidates and Recipients. Am J Transplant, 8: 1737–1743.
14. United States Food and Drug Administration (U.S. FDA). Fecal Microbiota for Transplantation: Safety Alert – Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms. Viewed 7 April 2020, https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission.
15. Agence Nationale de sécurité du Médicament (ANSM). La Transplantation de Microbiote Fécal et son Encadrement dans Les Essais Cliniques [Fecal Microbiota Transplantation and Its Supervision in Clinical Trials]. Viewed 1 September 2021, http://dev4-afssaps-marche2017.integra.fr/S-informer/Points-d-information-Points-d-information/La-transplantation-de-microbiote-fecal-et-son-encadrement-dans-les-essais-cliniques-Point-d-Information2.
16. Keller JJ, Vehreschild MJ, Hvas CL, et al. Stool for Fecal Microbiota Transplantation Should be Classified as a Transplant Product and Not as a Drug. United European Gastroenterol J, 7: 1408–1410.
17. Scheeler A. (2019). Where Stool is a Drug: International Approaches to Regulating the Use of Fecal Microbiota for Transplantation. J Law Med Ethics, 47: 524–540.